A Review of Treatment Options for Co-Occurring Methamphetamine Use Disorders and Depression

Hellem, Tracy L.; Lundberg, Kelly; Renshaw, Perry F.

doi:10.1097/jan.0000000000000058

Cited by 42 publications

(30 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, men may experience strong urges to use MA in response to negative affect, whereas women may place themselves in risky social situations (i.e., contexts where their peers are drinking or using) as they seek support for coping with negative affect. Understanding the specific trajectories and behaviors that differentiate men from women in their responses to negative affect may be valuable as a means of designing much needed gender-specific interventions (Hellem et al, 2015). For current alcohol users, women may be more susceptible to alcohol craving in response to negative mood induction than men (Rubonis et al, 1994).…”

Section: Discussionmentioning

confidence: 99%

“…Gender differences in psychiatric comorbidity have also been observed, where women with MUD are more likely than men to report symptoms of depression (Hser et al, 2005; Dluzen & Liu, 2008) and meet diagnostic criteria for major depressive disorder (MDD; Glasner-Edwards et al, 2009). Additionally, women with MUD appear more likely to report anxiety (Salo, et al, 2011), particularly social anxiety disorder (Glasner-Edwards et al, 2010a); however, less is known about the treatment of comorbid MUD and mood or anxiety disorders (Hellem, Lundberg, & Renshaw, 2015). …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sex Differences in the Association Between Internalizing Symptoms and Craving in Methamphetamine Users

Hartwell

Moallem

Courtney

et al. 2016

Journal of Addiction Medicine

View full text Add to dashboard Cite

Objectives Methamphetamine (MA) users often have substantial psychiatric comorbidities, with nearly a third reporting lifetime mood disorders and over a quarter reporting lifetime anxiety disorders. Female MA users are more likely to endorse depression and anxiety symptoms compared to men. Craving has been related to mood/anxiety symptoms in MA users. To extend the literature on gender differences in MA use disorder, the present study examines the role of gender as a moderator of the relationship between mood/anxiety symptoms and MA craving. Methods Participants (N = 203) were non-treatment seeking, current MA users, recruited from the Los Angeles community for enrollment in a larger pharmacotherapy trial. At the assessment visit, participants completed multiple measures including the Methamphetamine Urge Questionnaire, the Beck Depression Inventory, and the Beck Anxiety Inventory. Results The relationship between depression symptomatology and MA craving was moderated by gender (F = 6.18, p = 0.01), such that the relationship was positive and significant for men (p < 0.001) but was not significant for women. Similarly, gender significantly moderated the relationship between anxiety and MA craving (F = 5.99, p = 0.02), such that the relationship was also positive and significant in men but not in women (p < 0.001). Conclusions These results suggest that men may be more sensitive to the effects of internalizing symptoms on MA craving than women. Given craving's propensity to predict relapse, these initial findings indicate the necessity of treating comorbid psychiatric problems in male MA users, which may in turn assist in the attenuation of craving.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sex Differences in the Association Between Internalizing Symptoms and Craving in Methamphetamine Users

Hartwell

Moallem

Courtney

et al. 2016

Journal of Addiction Medicine

View full text Add to dashboard Cite

show abstract

“…Also, in this study, it was concluded that the symptoms of psychotic and mood symptoms could be important in both recurrence and prognosis of patients with methamphetamine abuse (5). On the other hand, due to the high comorbidity of depressive symptoms in people who abuse methamphetamine, it is hypothesized that the risk of other psychiatric disorders may underlie addiction or relapse of methamphetamine use (17).…”

Section: Discussionmentioning

confidence: 99%

Mental Health Assessment in Patients Admitted to Iran Psychiatric Hospital with a Diagnosis of Psychosis Due to 2 - 5 Years of Methamphetamine Use

Ahmadkhaniha

Alavi

Rouhi

et al. 2018

Int J High Risk Behav Addict

View full text Add to dashboard Cite

Background: Psychotic disorder due to methamphetamine has a high prevalence with an unknown nature and history. Patients with such disorders are faced with the risk of recurrence of abuse and other psychiatric disorders. Methamphetamine-induced psychotic disorders may continue by independent of methamphetamine abuse, such as primary psychotic disorders (such as schizophrenia). Objectives: This study was performed to evaluate the mental health and frequency of methamphetamine-induced psychosis in patients referred to Iran psychiatric hospital (a university hospital in Tehran, Iran). Patients and Methods: The research was done on patients with methamphetamine-induced psychosis after 2 to 5 years using of methamphetamine (150 person in the Iran Psychiatric Hospital) .The diagnostic interview was done based on a semi-structured interview (SCID). The data was analyzed by Binary Logistic Regression Model. Results: From 150 patients that were followed, 6 of them (4.0%) died during the phone interview-follow up. The mean age of alive patients was 34.9 ± 8.7 years and 12 of them were women (8.0%). At the follow-up interview, 38 patients reclassified as the cases of schizophrenia (25.3%), 17 as the cases of major depressive disorder (11.3%), 7 as the cases of bipolar disorder type I (4.7), two as the cases of schizoaffective disorder (1.3%), and two of them as the cases of delusional disorder (1.3%). A total of 84 cases (56.0%) were diagnosed as recovered cases or as methamphetamine-induced psychotic disorders. Prediction of diagnosis change showed the diagnosis of methamphetamine use disorder (adjusted OR = 3.978, 95% CI: 1.265-12.512), previous psychiatric admission (adjusted OR = 6.749; 95% CI: 1.639-27.779), and short duration of psychotic episode (adjusted OR = 0.171; 95% CI: 0.056-0.520. Conclusions: The results of our study show that methamphetamine-induced psychotic disorders are associated, in many cases, with the mood disorders. It seems that comorbid mood disorders, age of first use, history of previous psychiatric hospitalization, the risk of methamphetamine use disorders, and psychotic episodes are associated longer with the diagnosis towards primary psychotic disorders.

show abstract

“…It is well documented that short-and long-term methamphetamine use is associated with depression (DiMiceli, Sherman, Aramrattana, Sirirojn, & Celentano, 2016;Kalechstein et al, 2000;Nakama et al, 2008;Semple, Patterson, & Rant, 2009;Shoptaw, Peck, Redbackm, & Rotheram-Fuller, 2003) and that individuals with depression may self-medicate with methamphetamine (Hellem, Lundberg, & Renshaw, 2015;McKetin, Lubman, Lee, Ross, & Slade, 2011;Semple, Zians, Strathdee, & Patterson, 2007). The relationship between the symptoms of depression and methamphetamine intoxication and withdrawal complicates diagnosing major depressive disorder (MDD; Langa s, Malt, & Opjordsmoen, 2011) and measuring depression severity in methamphetamine users due to overlap in symptoms of depression and intoxicating effects of methamphetamine.…”

Section: Introductionmentioning

confidence: 99%

Preliminary Psychometric Evaluation of the Hamilton Depression Rating Scale in Methamphetamine Dependence

Hellem

Scholl

Sung

et al. 2017

Journal of Dual Diagnosis

View full text Add to dashboard Cite

Objective: The purpose of this study was to test the initial psychometric properties of the 17-item Hamilton Depression Rating Scale (HAM-D) in individuals with and without major depressive disorder who use methamphetamine. We used data from two completed studies and two ongoing clinical trials. The HAM-D has well established reliability and validity in a variety of populations. However, there are no published reports of reliability and validity of the HAM-D in a methamphetamine-using population. Methods: HAM-D and depression status data were extracted from four separate studies for this psychometric assessment. Using these data, we evaluated three measures of construct validity: internal consistency, contrasted group validity, and factorial validity. Results: We found potential concerns with the construct validity of the HAM-D in users of methamphetamine. Intercorrelations between items were primarily less than 0.20 and the Cronbach's alpha value in this sample was 0.58, indicating potential issues with internal consistency. The results of two-sample t-tests suggest concerns with contrasted group validity, as no significant difference in average scores were found for nine items. Consistent with previous studies, a principal component analysis indicates that the HAM-D is multidimensional. Conclusions: The 17-item HAM-D might not reliably and validly measure depression severity in a methamphetamine-using population. Given our small sample, additional research is needed, though, to further test the psychometric properties of the HAM-D in individuals who use methamphetamine.

show abstract

A Review of Treatment Options for Co-Occurring Methamphetamine Use Disorders and Depression

Cited by 42 publications

References 66 publications

Sex Differences in the Association Between Internalizing Symptoms and Craving in Methamphetamine Users

Sex Differences in the Association Between Internalizing Symptoms and Craving in Methamphetamine Users

Mental Health Assessment in Patients Admitted to Iran Psychiatric Hospital with a Diagnosis of Psychosis Due to 2 - 5 Years of Methamphetamine Use

Preliminary Psychometric Evaluation of the Hamilton Depression Rating Scale in Methamphetamine Dependence

Contact Info

Product

Resources

About